Raymond James & Associates Ultragenyx Pharmaceutical Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Raymond James & Associates holds 20,266 shares of RARE stock, worth $906,903. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,266

Previous 20,665 1.93%

Holding current value

$906,903

Previous $849,000 32.51%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$40.21 - $59.36 $16,043 - $23,684	-399 Reduced 1.93%	20,266 $1.13 Million
Q2 2024 Jul 19, 2024	BUY	$37.42 - $51.61 $5,388 - $7,431	144 Added 0.7%	20,665 $849,000
Q1 2024 Apr 22, 2024	BUY	$43.02 - $53.69 $248,053 - $309,576	5,766 Added 39.08%	20,521 $958,000
Q4 2023 Jan 16, 2024	SELL	$31.73 - $49.19 $94,904 - $147,127	-2,991 Reduced 16.85%	14,755 $705,000
Q3 2023 Oct 24, 2023	SELL	$34.92 - $46.66 $316,200 - $422,506	-9,055 Reduced 33.79%	17,746 $632,000
Q2 2023 Jul 25, 2023	BUY	$37.35 - $52.15 $102,077 - $142,525	2,733 Added 11.36%	26,801 $1.24 Million
Q1 2023 Apr 14, 2023	BUY	$36.99 - $48.71 $156,615 - $206,238	4,234 Added 21.35%	24,068 $965,000
Q4 2022 Feb 08, 2023	BUY	$33.72 - $46.33 $303,142 - $416,506	8,990 Added 82.9%	19,834 $918,000
Q3 2022 Oct 25, 2022	SELL	$39.96 - $66.14 $106,373 - $176,064	-2,662 Reduced 19.71%	10,844 $449,000
Q2 2022 Aug 12, 2022	SELL	$45.8 - $85.4 $17,220 - $32,110	-376 Reduced 2.71%	13,506 $806,000
Q1 2022 May 11, 2022	BUY	$62.2 - $84.4 $272,000 - $369,081	4,373 Added 45.99%	13,882 $1.01 Million
Q4 2021 Feb 08, 2022	SELL	$73.71 - $87.86 $24,250 - $28,905	-329 Reduced 3.34%	9,509 $800,000
Q3 2021 Nov 02, 2021	BUY	$77.92 - $102.4 $30,934 - $40,652	397 Added 4.21%	9,838 $887,000
Q2 2021 Aug 11, 2021	SELL	$92.19 - $115.71 $578,676 - $726,311	-6,277 Reduced 39.94%	9,441 $900,000
Q1 2021 May 14, 2021	BUY	$106.9 - $167.73 $640,331 - $1 Million	5,990 Added 61.57%	15,718 $1.79 Million
Q4 2020 Feb 12, 2021	BUY	$84.4 - $177.39 $304,852 - $640,732	3,612 Added 59.06%	9,728 $1.35 Million
Q3 2020 Nov 04, 2020	BUY	$72.98 - $90.0 $20,288 - $25,020	278 Added 4.76%	6,116 $503,000
Q2 2020 Jul 28, 2020	BUY	$46.91 - $78.22 $273,860 - $456,648	5,838 New	5,838 $457,000
Q2 2018 Aug 14, 2018	SELL	$48.54 - $85.31 $253,912 - $446,256	-5,231 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$44.33 - $58.52 $50,536 - $66,712	-1,140 Reduced 17.89%	5,231 $267,000
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $38,184 - $50,269	-877 Reduced 12.1%	6,371 $295,000
Q3 2017 Nov 13, 2017	BUY	$49.79 - $66.32 $6,871 - $9,152	138 Added 1.94%	7,248 $386,000
Q2 2017 Aug 14, 2017	BUY	N/A	7,110	7,110 $442,000

Others Institutions Holding RARE

# of Institutions

325

Shares Held

85.7M

Call Options Held

520K

Put Options Held

406K

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.13B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Ultragenyx Pharmaceutical Inc. Transaction History